Form 10-Q Vaxcyte, Inc. For: Sep 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Leerink Partners Reiterates Outperform Rating on Vaxcyte (PCVX)
November 6, 2024 5:59 AM ESTLeerink Partners analyst David Risinger reiterated an Outperform rating and $135.00 price target on Vaxcyte (NASDAQ: PCVX).
The analyst comments "Bottom Line: PCVX reported OpEx of $140M which was +2% or +$3M vs. our est. of $137M. The companys pipeline remains on track; the next readout to watch is VAX-24 Ph2 infant data at the end of 1Q25. We remain bullish on PCVX following competitive PCV pipeline commentary from PFE (MP) and GSK (Not Rated). PFE disclosed on its on... More
